Literature DB >> 66991

The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer.

T H Wasserman, S K Carter.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 66991     DOI: 10.1016/s0305-7372(77)80017-0

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  7 in total

1.  Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.

Authors:  J C Cervellino; C E Araujo; C Pirisi; O Sanchez; M Brosto; R Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Update in cancer chemotherapy: genitourinary tract cancer, Part 6: Cancer of the uterus and vulva.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1988-06       Impact factor: 1.798

3.  Occult advanced cervical cancer.

Authors:  B G Ward; J H Shepherd; J M Monaghan
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-04

4.  The clinical evaluation of analogues II. Bleomycins.

Authors:  S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

5.  Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study.

Authors:  G P Sutton; J A Blessing; L Adcock; K D Webster; T DeEulis
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850

6.  Stretching the Limits of Laparoscopy in Gynecological Oncology: Technical Feasibility of doing a Laparoscopic Total Pelvic Exenteration for Palliation in advanced Cervical Cancer.

Authors:  S P Puntambekar; G A Agarwal; S S Puntambekar; R M Sathe; A M Patil
Journal:  Int J Biomed Sci       Date:  2009-03

7.  Chemotherapy and molecular targeting therapy for recurrent cervical cancer.

Authors:  Naotake Tsuda; Hidemichi Watari; Kimio Ushijima
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.